2-methoxyestradiol alters cell motility, migration, and adhesion

Area of Science:

• Endocrinology
• Cell Biology
• Cancer Research

Background:

• 2-methoxyestradiol (2ME2) is an endogenous metabolite of 17beta-estradiol (E2).
• BCR-ABL transformation alters cell motility, adhesion, and migration.
• STI571 (imatinib mesylate) is a targeted therapy for BCR-ABL-positive cancers.

Purpose of the Study:

• To investigate the effects of 2ME2 on cell growth and cytoskeletal functions in BCR-ABL-transformed cells.
• To determine the interaction between 2ME2 and STI571 in drug-sensitive and -resistant cell lines.
• To explore 2ME2's potential as an anticancer therapeutic.

Main Methods:

• Utilized BCR-ABL-transformed cell lines (Ba/F3) and other cancer cell lines.
• Assessed cell growth inhibition, motility, adhesion to fibronectin, and cytoskeletal changes (tubulin formation).
• Investigated drug interactions with STI571 in sensitive and resistant models.

Main Results:

• 2ME2 inhibited growth of BCR-ABL-transformed cells and other cancer cell lines independently of BCR-ABL.
• STI571-resistant cells showed sensitivity to 2ME2.
• 2ME2 reduced spontaneous motility, adhesion to fibronectin, and altered cell morphology and tubulin formation.
• 2ME2 demonstrated efficacy in reducing spontaneous migration through transwell membranes.

Conclusions:

• 2ME2 significantly reduces cytoskeletal functions in transformed cells.
• 2ME2 exhibits anti-cancer properties, potentially useful for treating highly metastatic cancers.
• Combination therapy with 2ME2 and other anticancer drugs may benefit drug-resistant cancers.